Ivan Đikić is Professor of Biochemistry and Director of the Institute of Biochemistry II at the Goethe University and a Fellow at the Max Planck Institute for Biophysics in Frankfurt.
He was trained as a medical doctor in Zagreb, Croatia and obtained his PhD under supervision of Joseph Schlessinger at the New York University, USA. From 1997-2002 he was a Group Leader at the Ludwig Institute for Cancer Research, Uppsala, Sweden. He joined Goethe University in 2003 and became Director of the Institute of Biochemistry II in 2009.
Ivan Đikić is a leading expert in the fields of ubiquitin biology and autophagy with his lab focusing on exploring pathological alterations in these pathways related to human diseases e.g. cancer, infection diseases and neurodegeneration. His recent interests focus on mechanisms of ER remodelling and discovery of novel proximity-inducing drugs including PROTACs and molecular glues.
Besides being the Speaker of the collaborative research centre on selective autophagy since 2016, he more recently established two large research consortia at Goethe University (ENABLE and PROXIDRUGS) with the aim to utilize new technologies toward drug development, in particular using proximity-inducing mechanisms for targeted protein degradation.
He is an elected member of the EMBO, the German National Academy of Sciences Leopoldina, the European Academy and the American Academy of Arts and Sciences. For his scientific work he received multiple awards including the Louise-Jeantet Prize for Medicine, the Hans Krebs Award, the Jung Prize for Medicine and the Leibniz Prize. Ivan Đikić is committed to education of the next generations of young scientists globally and spends significant time and energy in science. His educational and scientific accomplishments were recognized by the highest civilian state honors in Croatia – the Order of Duke Branimir, bestowed by the President of Croatia.
Web: https://biochem2.com/research-group/molecular-signaling
LinkedIn: https://www.linkedin.com/in/ivan-đikić-a7b53527/
